Načítá se...
EGFR突变晚期非小细胞肺癌患者后线接受免疫治疗的疗效分析
BACKGROUND AND OBJECTIVE: Immune checkpoint inhibitor monotherapy is reported to have little effect in advanced non-small cell lung cancer (NSCLC) patients with driver oncogenes. However, recent studies have shown that some patients with driver genes are still benefit from combination immunotherapy...
Uloženo v:
| Vydáno v: | Zhongguo Fei Ai Za Zhi |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
中国肺癌杂志编辑部
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8174113/ https://ncbi.nlm.nih.gov/pubmed/34034457 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3779/j.issn.1009-3419.2021.104.06 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|